ReviewHepatology international2018
Biology of portal hypertension.
Review in Hepatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 109 citations in OpenAlex.
- Splanchnic hemodynamic parameters measured with 4D flow MRI can diagnose severe portal hypertension.European radiology · 2026Article
- A Retrospective Cohort Study on Hassab's Surgery as a Salvage Treatment for Patients with Secondary Prophylaxis Failure for Acute Variceal Bleeding.Journal of clinical medicine · 2025Article
- Association between the triglyceride glucose-body mass index and cardiometabolic diseases risk in chronic liver disease: a nationwide cohort study.European journal of medical research · 2025Article
- The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.Biomedicines · 2025Review
- The potential roles of gut microbiome in porto-sinusoidal vascular disease: an under-researched crossroad.Frontiers in microbiology · 2025Review
- Gut dysbiosis contributes to the development of Budd-Chiari syndrome through immune imbalance.mSystems · 2024Article
- Direct oral anticoagulants in cirrhosis: Rationale and current evidence.JHEP reports : innovation in hepatology · 2024Review
- Article
- Implication of Hypotension in the Pathogenesis of Cognitive Impairment and Brain Injury in Chronic Liver Disease.Neurochemical research · 2024Review
- Article
- Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension.iScience · 2024Article
- Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease.Gut and liver · 2024Review
- Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine.Frontiers in pharmacology · 2024Review
- Recent Approaches in Portal Hypertension Involving Risk Stratification and Medical Management.Gastroenterology & hepatology · 2023Article
- [Research progress of liver sinusoidal endothelial cells in nonalcoholic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Review
- Systemic TM4SF5 overexpression in ApcBMB reports · 2022Article
- The role of JAK inhibitors in hematopoietic cell transplantation.Bone marrow transplantation · 2022Review
- Detection of liver and spleen stiffness in rats with portal hypertension by two-dimensional shear wave elastography.BMC medical imaging · 2022Article
- ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.Journal of clinical medicine · 2022Article
- Covid-19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis.Hepatology communications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Portal hypertension develops as a result of increased intrahepatic vascular resistance often caused by chronic liver disease that leads to structural distortion by fibrosis, microvascular thrombosis, dysfunction of liver sinusoidal endothelial cells (LSECs), and hepatic stellate cell (HSC) activation. While the basic mechanisms of LSEC and HSC dysregulation have been extensively studied, the role of microvascular thrombosis and platelet function in the pathogenesis of portal hypertension remains to be clearly characterized. As a secondary event, portal hypertension results in splanchnic and systemic arterial vasodilation, leading to the development of a hyperdynamic circulatory syndrome and subsequently to clinically devastating complications including gastroesophageal varices and variceal hemorrhage, hepatic encephalopathy from the formation of portosystemic shunts, ascites, and renal failure due to the hepatorenal syndrome. This review article discusses: (1) mechanisms of sinusoidal portal hypertension, focusing on HSC and LSEC biology, pathological angiogenesis, and the role of microvascular thrombosis and platelets, (2) the mesenteric vasculature in portal hypertension, and (3) future directions for vascular biology research in portal hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.